Similarly, a prospective study comparing the performance of gallium-68 ([68Ga])-labeled FAP inhibitor (FAPI) and [18F]-FDG for the evaluation of joint disease activity in RA showed that [68Ga]-FAPI demonstrates a greater amount and degree of affected joints than [18F]-FDG. This evidence concerns the gene FAP and rheumatoid arthritis.